9,10-Anthracenedione, 1-[[2-[(2-hydroxyethyl)amino]ethyl]amino]- | 105580-93-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 蒽
• 英文名称: 9,10-Anthracenedione, 1-[[2-[(2-hydroxyethyl)amino]ethyl]amino]-
• 英文别名: 1-[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione
• CAS: 105580-93-6
• 化学式: C₁₈H₁₈N₂O₃
• 分子量: 310.3
• InChiKey: GTHICKVZNHXYII-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  78.4
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• HETERO-ANNULATED INDAZOLES
  申请人：Novuspharma S.p.A.

  公开号：EP0750619B1

  公开（公告）日：2001-05-30
• HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS
  申请人：THE UNIVERSITY OF ROCHESTER

  公开号：EP1903873A2

  公开（公告）日：2008-04-02
• METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY
  申请人：West Michael D.

  公开号：US20100184033A1

  公开（公告）日：2010-07-22

  Aspects of the present invention relate to methods to differentiate pluripotent primordial stem cells, such as human embryonic stem (“hES”) cells, human embryonic germ (“hEG”) cells, human embryo-derived (“hED”) cells and human embryonal carcinoma (“hEC”) cells, to obtain subpopulations of cells from heterogeneous mixtures of cells, wherein the subpopulation of cells possess reduced differentiation potential compared to the original pluripotent stem cells and where the subpopulation is capable of being propagated 20 or more population doublings. This invention also provides novel compositions of such subpopulations of cells and methods to propagate and differentiate said cells.
• US5935969A
  申请人：——

  公开号：US5935969A

  公开（公告）日：1999-08-10
• [EN] HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS<br/>[FR] COMPOSITIONS A BASE DE VIRUS HERPETIQUE ET PROCEDES D'UTILISATION DANS LES PERIODES PRENATALES ET PERINATALES
  申请人：UNIV ROCHESTER

  公开号：WO2006135602A2

  公开（公告）日：2006-12-21

  [EN] Disclosed are compositions and methods for reducing the severity of a birth defect in a mammal by exposing the mammal (e.g., in utero) to a herpes virus amplicon particle comprising a cis element-flanked transgene and a sequence encoding a transposase. Upon expression, the transposase inserts the transgene into the genome of a cell (e.g., a neuron) within the mammal and the transgene expresses a polypeptide or RNA that compensates for a protein or gene defect that is causally associated with the birth defect.
  [FR] L'invention concerne des compositions et des procédés de réduction de la gravité d'une anomalie à la naissance chez un mammifère consistant à exposer le mammifère (par exemple in utéro) à une particule d'amplicon de virus herpétique contenant un transgène flanqué d'un élément cis et une séquence codant une transposase. Lors de l'expression, la transposase insère le transgène dans le génome d'une cellule (par exemple un neurone) à l'intérieur du mammifère et le transgène exprime un polypeptide ou un ARN qui compense une anomalie protéique ou génique associée par effet de causalité à l'anomalie à la naissance.